Defining Melanoma Quality Indicators: A Modified Delphi Approach
Apurva Shirodkar(Cancer Care Ontario), Frances C. Wright(Saint John's Health Center), Myles Smith(Royal Marsden NHS Foundation Trust), Leta Forbes(Cancer Care Ontario), Rachael L. Morton(University of Sydney), An‐Wen Chan(World Health Organization), Marc Moncrieff(Norfolk and Norwich University Hospital), Brandon S. Sheffield(BC Cancer Agency), Carolyn Nessim(University of Ottawa), Annette Cyr(Oakville Public Library), Renee Hanrahan(McMaster University Medical Centre), Susan Blacker(Cancer Care Ontario), Aaron Pollett(Mount Sinai Hospital), Timothy P. Hanna(Queen's University), Kevin Higgins(Sunnybrook Health Science Centre), Mark B. Faries(Angeles Clinic and Research Institute), Aliya Pardhan(Cancer Care Ontario), Anthony M. Joshua(St Vincent's Hospital Sydney), Teresa M. Petrella, Christian Murray(University of Toronto), Brian Hasegawa(Western University), Sandy Salama(Cancer Care Ontario), Darren C. Cargill(Cancer Care Ontario), Marcus O. Butler(University of Toronto)
Cited by 0
Related Papers
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k